Skip to main content
. 2022 Dec 26;114(4):1686–1696. doi: 10.1111/cas.15703

FIGURE 2.

FIGURE 2

(A) Comparison of miR‐192‐5p levels in plasma between healthy volunteers (HV) and esophageal cancer (EC) patients without neoadjuvant chemotherapy (NAC). miR‐192‐5p levels were significantly higher in EC patients than HV. Mann–Whitney U test was used to analyze the data (**p < 0.01). (B) miR‐192‐5p levels in plasma from EC patients after NAC (plasma before surgery). Patients were distributed by response of NAC (grade 1, grade 2, and grade 3), and miR‐192‐5p levels among the three groups were compared. miR‐192‐5p level was significantly higher in EC patients with grade 3 cancer compared with the other grades. Mann–Whitney U test was used to analyze the data (*p < 0.05). (C) Recurrence‐free survival (RFS) curves for EC patients without NAC. A high level of miR‐192‐5p in plasma was associated with a poor prognosis in RFS (p = 0.007). (D) RFS curves of EC patients with NAC and with the response of NAC were grade 1 or 2. A high level of miR‐192‐5p was associated with poor prognosis in RFS (p = 0.010).